[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100475302":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":31,"locations":42,"responsibleParty":59,"collaborators":61,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":67,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":30,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":45,"whyStopped":30,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Laval University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Cyproheptadine 4 Mg Oral Tablet","EXPERIMENTAL","Participants will receive cyproheptadine 4mg tablet orally three times a day for three months, with a daily increase of 4mg\u002Fdose if the previous dose was well tolerated, up to 0.5 mg\u002Fkg\u002Fday.",[13],"Drug: Cyproheptadine 4 Mg Oral Tablet",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Participants will receive a matched placebo orally three times a day for 3 months. Daily titration similar to the treatment arm.",[19],"Other: Placebo",[21,27],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Cyproheptadine treatment for 3 months",[9],[26],"Cyproheptadine",{"type":6,"name":15,"description":28,"armGroupLabels":29,"otherNames":30},"Placebo administration for 3months",[15],null,[32,38],{"name":33,"role":34,"phone":35,"phoneExt":36,"email":37},"Jonathan Beaudoin, MD","CONTACT","(418) 656-8711","2943","jonathan.beaudoin@criucpq.ulaval.ca",{"name":39,"role":34,"phone":35,"phoneExt":40,"email":41},"Ons Marsit, PhD","5773","ons.marsit.1@ulaval.ca",[43],{"facility":44,"status":45,"city":46,"state":30,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval","RECRUITING","Québec","G1V 4G5","Canada","CA",{"type":51,"coordinates":52},"Point",[53,54],-71.21454,46.81228,{"lat":54,"lon":53},[57],{"name":33,"role":34,"phone":58,"phoneExt":36,"email":30},"418 656-8711",{"type":60,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR",[62],{"name":63,"class":64},"Canadian Institutes of Health Research (CIHR)","OTHER_GOV","100475302","phase-2-serotonin-receptor-blockers-in-ischemic-mitral-regurgitation-100475302",false,"NCT05469165","Serotonin Receptor Blockers in Ischemic Mitral Regurgitation","Blocking the Effects of Serotonin to Prevent Ischemic Mitral Regurgitation: a Randomized Trial (CYPRO-MR)","CYPRO-MR","Inclusion Criteria:\n\n1. Patients 18-80 years old with a 1st episode of STEMI with documented coronary obstruction.\n2. Left ventricle ejection fraction (LVEF)\\\u003C50% and mitral tenting area ≥ 4 cm2, OR LVEF ≤ 40% and inferior\u002Fposterior wall motion anomaly, OR LVEF≤30% and wall motion in any territory.\n\nExclusion Criteria:\n\n1. Inability to provide informed consent\n2. Hemodynamic instability \u002F cardiogenic shock \u002F papillary muscle rupture\n3. Prior mitral valve procedure\u002Fsurgery\n4. Permanent atrial fibrillation (limiting imaging and MR quantification)\n5. Primary mitral disease (endocarditis, rheumatic, degenerative or congenital)\n6. More than mild valvular disease (other than mitral) at baseline\n7. Planned cardiac surgery (CABG or valve intervention) within 3 months\n8. Contraindications for MRI\n9. Ongoing treatment with selective serotonin reuptake inhibitor (SSRI)\n10. Chronic use of sedative medication\n11. Ongoing or planned pregnancy\n12. Chronic renal failure with Estimated Glomerular Filtration Rate (eGFR) \\\u003C 30 mL\u002Fmin\n13. Neurocognitive disorder\n14. Symptom or prior episode of urinary obstruction or glaucoma (relative contraindications for cyproheptadine)","ALL","18 Years","80 Years",{"count":77,"type":78},214,"ESTIMATED","INTERVENTIONAL",[81],"PHASE2","This study is intended to investigate the effect of cyproheptadine (a 5HT2B receptor blocker) on mitral regurgitation severity.",[84],"Ischemic Mitral Regurgitation",[86,87,88,89,26],"Ischemic mitral regurgitation","Myocardial infarction","Mitral valve","Serotonin","2023-11-13",{"date":92,"type":93},"2023-11-15","ACTUAL",{"date":95,"type":93},"2023-06-20",{"date":97,"type":78},"2027-09",{"name":5,"class":6},1]